Pharmaceutical Microbiology is the branch of Microbiology, which involves the study of microorganisms associated with the manufacture of pharmaceuticals. e.g. controlling the number of microorganisms in a process environment, excluding microorganisms and microbial by-products like exotoxin and endotoxin from water and other starting materials, and ensures the sterile finished pharmaceutical product. Pharmaceutical microbiology includes the research and development of anti-infective agents, where the use of microorganisms to detect mutagenic and carcinogenic activity in prospective drugs, and in the manufacture of pharmaceutical products likes insulin and human growth hormone.
Microbiology contains numerous sub-divisions which include:
Pharmaceutical Biotechnology is simply defined as, the science that covers all the technologies required for the production, manufacturing, and registration of biological drugs.
It Includes:
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Preparation and characterization of fibers crafted from PCL/PVP-ChAgG, coupled with investigating their suitability as wound dressings.
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Is your drug delivery formulation harming the environment ? Approaches to both save human health and the environment
Thomas J. Webster, School of Health Sciences and Biomedical Engineering and Mansfield Bioincubator, China
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland